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Abstract
Background/Aims: We evaluated clinicopathological correlates of upper motor neuron (UMN) damage in amyotrophic
lateral sclerosis (ALS), and analyzed if the presence of the C9ORF72 repeat expansion was associated with alterations in
microglial inflammatory activity.
Methods: Microglial pathology was assessed by IHC with 2 different antibodies (CD68, Iba1), myelin loss by Kluver-Barrera
staining and myelin basic protein (MBP) IHC, and axonal loss by neurofilament protein (TA51) IHC, performed on 59 autopsy
cases of ALS including 9 cases with C9ORF72 repeat expansion.
Results: Microglial pathology as depicted by CD68 and Iba1 was significantly more extensive in the corticospinal tract (CST)
of ALS cases with a rapid progression of disease. Cases with C9ORF72 repeat expansion showed more extensive microglial
pathology in the medulla and motor cortex which persisted after adjusting for disease duration in a logistic regression
model. Higher scores on the clinical UMN scale correlated with increasing microglial pathology in the cervical CST. TDP-43
pathology was more extensive in the motor cortex of cases with rapid progression of disease.
Conclusions: This study demonstrates that microglial pathology in the CST of ALS correlates with disease progression and is
linked to severity of UMN deficits.
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Introduction
Amyotrophic lateral sclerosis (ALS) is the most frequent adult-
onset motor neuron disease, characterized by the combined
degeneration of the upper motor neurons (UMN) of the
corticospinal tract (CST) and the lower motor neurons (LMN) of
the spinal cord anterior horns, leading to death after a mean
survival of approximately three years [1]. Neuronal degeneration
in ALS is accompanied by the presence of hallmark ubiquitinated
cytoplasmic inclusions, which were shown to be formed by the 43-
kDa TAR DNA-binding protein (TDP-43) in the majority of ALS
cases [2]. Genetically, ALS is mostly sporadic (sALS) but
approximately 10% of cases have a first- or second-degree relative
with the disease suggestive of familial ALS (fALS). Mutations in
SOD1, encoding the Cu/Zn superoxide dismutase, TARDBP
encoding TDP-43, fused in sarcoma (FUS) and the optineurin
(OPTN) gene were observed to account for ,30% of fALS cases
[3–7]. Recently, a noncoding GGGGCC hexanucleotide repeat
expansion in the C9ORF72 gene was identified as the most
common genetic abnormality in fALS and sALS [8–10]. ALS and
frontotemporal lobar degeneration (FTLD) cases with C9ORF72
expansion were observed not to contain protein aggregates
comprised of the C9ORF72 protein [10,11] though TDP-43
inclusions were observed and p62 was suggested to be the major
disease protein since p62-immunoreactive neuronal cytoplasmic
inclusions were found in the cerebral cortex, basal ganglia,
hippocampus, and cerebellum [6,9,12].
A major conceptual advance was the notion that ALS is not an
autonomous disease of neurons, but a multiple-system disease with
an important role played by astrocytes [4,5,13–15] and microglia
[6,16,17]. Several studies demonstrated extensive microglial
pathology in cases with ALS [18–20], and inflammatory
mechanisms, including microglia, have been implicated in
mediating neuronal cell death as well as promoting neuronal
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shown to have beneficial effects on survival in transgenic mouse
models of ALS [24,25], though this has not been substantiated in
human ALS clinical trials so far [26,27]. This notwithstanding,
glial cells are likely to have an impact on disease pathology in ALS
that goes far beyond the notion of an unspecific response to
neuronal degeneration.
Although the relevance of microglia in ALS pathology is well
established, few studies have systematically related microglial
pathology to the clinical phenotype of ALS [20,28]. It is
furthermore unclear how the presence of the C9ORF72 repeat
expansion affects non-neuronal cells involved in ALS pathology
and if it is associated with alterations in microglial inflammatory
activity. Here, we describe neuropathological findings in a large
and clinically well-defined cohort of ALS and evaluate the
relevance of C9ORF72 gene mutations to microglial pathology
and clinical phenotypes, focusing on motor symptoms and
progression of disease.
Methods
Ethics Statement
The study was performed according to the provisions of the
Helsinki Declaration. Written informed consent was obtained
from all autopsy cases or their next of kin, and the study was
approved by University of Pennsylvania Institutional Review
Board (Penn IRB).
Autopsy Cohort
Individuals who underwent autopsy in the Center for Neuro-
degenerative Disease Research at the University of Pennsylvania
from 2004 to 2010 were enrolled. Our cohort included 59 cases
with a clinical diagnosis of definite ALS in accordance with the
modified El Escorial Criteria [29] and a neuropathological
diagnosis of ALS (Table 1). Detailed clinical characteristics
(gender, age at onset, age at death, site of onset, disease duration,
ALS global disease severity as measured by a functional rating
score (ALSFRS-R) [30], and the Medical Research Council
Sumscore (MRCS) [31] were ascertained by retrospective chart
review of clinic visits from 2004 through 2010 at the ALS Center
within the University of Pennsylvania Health System; the vast
majority of patients had been seen by two neurologists (L.E.,
L.M.). Unless otherwise specified, results of clinical testing used in
this study were from the visit most proximate to the patients’
death, occurring within 3 months of death. Of the ALS cases
included here, 11 (18.6%) had a family history of ALS, 12 (20.3%)
had a family history of other neurodegenerative diseases, 32
(54.2%) were sporadic, and for 4 cases (6.8%) family history was
unknown. The mean postmortem interval to autopsy for this
cohort was 12.4 (+/27.1 hours).
Score to Assess UMN Involvement
To obtain a parametric scale of UMN involvement, patients
were graded in terms of UMN ‘‘burden’’, using a novel score that
combined an assessment of spasticity based on the Ashworth
Spasticity Scale [32] with reflex scoring [33], and rating of
pseudobulbar affect [34]. In brief, spasticity for each extremity was
rated from ‘‘0’’ (indicating no increase of muscle tonus) to ‘‘2’’
(indicating considerable increase in tone equivalent to rigidity of
the extremity). In addition, three reflexes for each extremity were
scored (upper extremity: biceps reflex, triceps reflex, finger flexors;
lower extremity: patellar reflex, crossed adduction, ankle reflex),
with the score ranging from ‘‘0’’ (normal or absent reflex) to ‘‘1’’
(pathologically brisk or retained reflex in a paretic extremity).
Furthermore, the presence or absence of muscle clonus and
pyramidal signs (e.g. Babinski sign, Hoffman’s sign) was scored, as
was the presence or absence of pseudobulbar affect (‘‘0’’ indicating
absence, ‘‘1’’ indicating presence of these signs). This led to a
comprehensive score of UMN involvement ranging from a
minimum of 0 (no signs of UMN involvement) to a maximum of
32 (severe UMN involvement). A detailed description of the score
is provided as supporting Table 1 (Table S1).
Basic Neuropathological Characterization
Pathology was examined in the grey and white matter of 4
regions of the central nervous system (CNS) extending over the
whole length of the neuraxis: motor cortex (precentral gyrus),
medulla oblongata, cervical spinal cord (CSC), and lumbar spinal
cord (LSC). For the spinal cord sections, the grey matter
examined was the anterior horn and the white matter examined
was the anterior and lateral portion of the CST. Sections were
fixed and cut into 6–10 mm sections, stained with hematoxylin
and eosin (H&E) and Thioflavin S, and immunohistochemistry
(IHC) was performed with antibodies to tau, a-synuclein,
ubiquitin, and TDP-43 as previously described [2,35–37]. The
extent of TDP-43, tau and plaque pathology as well as the extent
of neuron loss (as monitored by HE) were rated for each region
on a 4-point ordinal scale (0, none; 1, mild; 2, moderate; 3,
severe/numerous) [38,39].
Analysis of Microglial Pathology and Axonal Loss
Sections of 6–10 mm thickness were cut from paraffin-
embedded specimens. For IHC all slides were deparaffinized
and rehydrated in a series of xylene and graded ethanol. After
immersion in methanol/H2O2 for 30 min, slides were washed in
0.1 M Tris buffer (pH 7.6) and blocked in 0.1 M Tris/2% FBS.
Sections were stained using polyclonal rabbit anti-Iba1 antibody
(Wako Chemicals, Richmond, VA) at 1:1.000 and incubated
overnight at 4uC. Sections were then rinsed and washed in Tris
and incubated with Vector biotinylated anti-rabbit IgG (Vector
Laboratories Inc., Burlingame, Ca) at 1:1.000 for 1 h. After
rinsing again the ICH reaction was visualized using 3,39-
diaminobenzidine (DAB) and the sections were dehydrated
through graded ethanol, cleared in xylene, and coverslipped in
Cytoseal 60 mounting medium. Sections were stained for CD68
using mouse anti-human CD68 (Dako, Carpinteria, CA) at
1:1.000. The extent of microglial activation was rated for each
region on a 4-point ordinal scale (0, none; 1, mild; 2, moderate;
3, severe/numerous) as previously described [38,39] (Figure 1).
Staining for myelin basic protein (MBP) was performed as
described before [40], as was Kluver-Barrera (KB) staining, while
IHC for the phosphorylated species of the two neurofilament
heavy chains (Nf) was used to assess axonal loss in the anterior
and lateral CST of these ALS subjects. Staining of Nf was
performed using TA51 which recognizes a phosphorylation-
dependent epitope in the carboxy terminus of the high and
middle molecular weight NF subunits as described [41,42]. The
primary antibody (supernatant) was used at 1:200. This antibody
is considered highly specific of Nf and does not cross-react with
other cytoskeletal proteins [15].
Double-labeling immunofluorescence (IF) analyses were per-
formed as previously described [2] using Alexa Fluor 488- and
594-conjugated secondary antibodies (Molecular Probes, Eugene,
OR), treated for autofluorescence with Sudan Black solution [43],
and coverslipped with Vectashield-DAPI mounting medium
(Vector Laboratories). Fluorescence images were obtained using
a Leica TCS SPE-II scanning laser confocal microscope.
Microglia and Motor Symptoms in ALS
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Genomic DNA was extracted from peripheral blood or brain
tissue following the manufacturer’s protocols (Flexigene (Qiagen,
Valencia, CA) or QuickGene DNA whole blood kit L (Autogen,
Holliston, MA) for blood, and QIAsymphony DNA Mini Kit
(Qiagen) for brain). Genotyping for a C9ORF72 repeat expansion
was performed as described previously (Renton et al., 2011) with
minor modifications. Briefly, repeat-primed PCR was performed
using 100 ng of DNA in a final volume of 28 ml containing (final
concentrations): Roche (Indianapolis, IN) FastStart PCR Master
Mix (1X), DMSO (7%, Sigma-Aldrich, St. Louis, MO), betaine
(0.93M, Sigma-Aldrich, St. Louis, MO), deazaGTP (0.18 mM,
Roche, Indianapolis, IN), MgCl2 (0.9 mM, Sigma-Aldrich, St.
Louis, MO), and 10X primer mix (1X). The 10X primer mix was
prepared containing 14 mM 6-FAM labeled forward primer (6-
FAM-5‘AGTCGCTAGAGGCGAAAGC), 7 mM reverse repeat
primer (5‘TACGCATCCCAGTTTGA-
GACGGGGGCCGGGGCCGGGGCCGGGG), and 14 mM an-
chor tail reverse primer (5‘TACGCATCCCAGTTTGAGACG).
Touchdown PCR cycling conditions consisted of 4 min at 95uC
followed by cycles of 95uC for 30 sec, annealing between 70uC–
56uC for 1 minute, and extension at 72uC for 3 min, ending with a
final extension step of 10 min at 72uC. The annealing temperature
is decreased by 2uC in each step starting at 70uC for 2 cycles, 68uC
for 3 cycles, 66uC for 4 cycles, 64uC for 5 cycles, 62uC for 6 cycles,
60uC for 7 cycles, 58uC for 8 cycles, and 56uC for 5 cycles. PCR
product (2 ml) was mixed with 0.5 ml of ROX 500 Size Standard
(Life Technologies, Carlsbad, California) and 7.5 ml Hi-Di
formamide (Life Technologies, Carlsbad, California) and evaluat-
ed on an ABI 3130 capillary electrophoresis instrument with
POP7 polymer and a 36 cm capillary with a 23 sec injection time.
Interpretation of a positive expansion case was based on the
presence of a stutter pattern while that of a case lacking the
expansion produced one or more peaks with an abrupt ending
peak. In some cases the absence of an expansion was confirmed
using a standard 2 primer PCR reaction across the repeat region.
The presence of 2 unique peaks was interpreted as negative for a
repeat expansion while the identification of only a single peak was
not informative. This 2 primer genotyping was performed using
primers from by DeJesus-Hernandez et al with minor protocol
modifications (Dejesus-Hernandez et al., 2011). Briefly, the PCR
was performed using 50 ng of DNA in a final volume of 20 ml
containing (final concentrations): Amplitaq Gold buffer (1X),
DMSO (5%), betaine (1 M), dNTP mixture with 7-deazaGTP
instead of dGTP (0.25 mM each), MgCl2 (0.9 mM), forward and
reverse primers (1 mM each), and Amplitaq Gold polymerase
0.5 U/reaction (Life Technologies, Carlsbad, California). PCR
cycling conditions consisted of 10 min at 94uC followed by 36
cycles of 94uC for 35 sec, annealing between 62uC for 2 min, and
extension at 72uC for 1 min, ending with a final extension step of
10 min at 72uC. The ABI 3130 electrophoresis conditions for this
assay are the same as for the repeat-primed PCR reaction.
Statistical Analysis
The ‘‘average’’ (and ‘‘range’’) of data on patient characteristics
was estimated by calculating the median (and 25th-75th percen-
tiles). Differences between two groups were compared using
Wilcoxon Mann-Whitney Test for quantitative and ordinal
variables. To compare raw data of multiple groups, Kruskal-
Wallis analysis of variance on ranks was applied, followed in case
of significance by Dunn’s Method in case. All correlations were
studied using Spearman’s rank order correlation coefficient.
Bonferroni-correction for multiple testing was applied when
contrasts were not driven by a specific hypothesis. For all other
tests, p-values ,0.05 were considered significant. All statistical
tests were 2-sided. A logistic ordinal regression model was used to
test the association between the degree of microglial staining
(dependant variable) and the presence of C9ORF72 expansions,
adjusting for disease duration. Data analysis was performed using
SPSS (Version 17.0 SPSS Inc., Chicago, IL, USA).
Results
Microglial Pathology as Depicted by CD68 and Iba1
To evaluate microglial pathology in the neuraxis of ALS, IHC
with two different markers, CD68 and Iba1 was performed.
Morphologically, activated microglial cells were observed to show
a thin and elongated shape. In other reactive areas, a bushy and
increasingly ramified morphology of microglial cells could be
found (Figure 1). In the ventral horns of ALS spinal cord sections,
an increased density of Iba1- and CD68-positive cells with
enlarged cell processes, often in close proximity to motor neurons
was observed. The density of ramified cells decreased in white
matter regions containing the degenerating CST; instead,
microglia transitioned to rounded macrophages (‘‘myelino-
phages’’) of varying sizes. These myelinophages were observed
most extensively in the lateral and anterior cervical and lumbar
CST of ALS, and where best visualized by CD68 IHC (Figure 1).
Table 1. Demographic data of ALS autopsy cases included in this study.
ALS all ALS C9+ ALS C92 S
N (female/male) 59 (19/40) 9 (2/7) 50 (17/33)
Bulbar onset (n) 18 (30.5%) 5 (55.6%) 13 (26%) p=0.04
Median (interquartile range)
Age at onset [years] 59 (52.5–67) 56 (53.8–63.3) 59 (52–68) NS
Age at death [years] 62 (56–70) 59 (56.3–65.3) 63 (56–72) NS
Disease duration [months] 24 (18–45) 24 (21–30) 30.6 (18–48) NS
ALSFRS-R 19 (14.8–24.3) 26 (21–31.3) 19 (14–22.5) p=0.02
MRCS 39.5 (34.5–48) 45.5 (37–55) 38.5 (34–46.5) NS
UMN Score 10 (2.75–17) 4 (1.5–17.8) 10.5 (4–17) NS
ALSFRS-R = revised ALS functional rating scale, MRCS = Medical Research Council Sumscore, NS = not significant, UMN = upper motor neuron, S = statistical
significance.
doi:10.1371/journal.pone.0039216.t001
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CD68 with Iba1 labeling mainly the cytoplasm and ramifications
of microglia while CD68 mainly stained dot-like intracellular
microglial compartments suggestive of endosomes/lysosomes, and
phagosome-like profiles in macrophages (Figure S1).
Microglial pathology was most extensive in the cervical and
lumbar CST (Figure 2). Neuronal loss was most extensive in
cervical and lumbar anterior horns and axonal loss was most
extensive in the cervical and lumbar CST which was reflected by
IHC for CD68, Iba1 and TDP-43 as well as by myelin staining
(Figure 2). Microglial pathology as measured by Iba1 correlated
with axonal loss (as indirectly reflected by reductions in KB
staining) in white matter subjacent to motor cortex (rho =0.40,
p=0.02, and rho =0.47, p=0.01, respectively). The extent of
microglial pathology as detected by both CD68 and Iba1
correlated with cervical CST axonal loss as reflected by reductions
in KB staining and IHC for Nf proteins and MBP (rho .0.4,
p,0.01 each). Microglial pathology as measured by Iba1
correlated with neuronal loss as measured by H&E staining of
lumbar anterior horn sections (rho =0.4, p=0.03).
TDP-43 pathology was observed throughout the grey matter of
the neuraxis, with the most extensive TDP-43 positive inclusion
pathology found in the anterior horn of the CSC (Figure 2). TDP-
43 neuronal cytoplasmic inclusions varied in morphology from
Figure 1. Staging of CST degeneration in ALS. The figure illustrates the IHC staging used to grade the extent of microglial activation (CD68,
Iba1) and axonal loss (MBP, KB, NF) in the CST of ALS patients. Images are taken from the lateral portion of the cervical CST. KB = Kluver-Barrera,
MBP= myelin basic protein, NF = neurofilaments (TA51). Large images were taken with 46objective, Scale bar is 1.0 mm. Small insert images were
taken with 606objective. Small insert image for CD68 stage ‘‘0’’ shows prominent neuronal nuclei, but no activated microglia.
doi:10.1371/journal.pone.0039216.g001
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tous skeins. In the neuraxis white matter analyzed here, only rare
glial TDP-43 pathology was observed which was consistent with
oligodendroglial TDP-43 inclusions. No correlation of TDP-43
pathology with neuronal or axonal loss as measured by any of the
staining used here was observed in any of the regions analyzed (rho
,0.4, p.0.05 each). The extent of microglial pathology and TDP-
43 did not show a significant difference in any of the regions
analyzed here between patients with sALS and fALS.
Relation of Microglial Pathology and TDP-43 to
Progression of Disease
We next asked if microglial pathology was linked to the clinical
phenotype including progression of disease. The median disease
duration to death for the entire cohort of ALS autopsy cases was
24 months (Table 1). Patients with a disease duration shorter/
equal to the median (n=27) were defined as showing a rapid
progression of disease [44], while cases with disease duration
longer than 24 months (n=26) were defined as showing a slow
progression of disease (for 7 patients data on disease progression
was missing). Cases with a rapid progression of disease showed
more extensive microglial pathology as illustrated by CD68 IHC
results in most of the regions analyzed here (p,0.05 each,
Figure 3), with the exception of the CSC and motor cortex white
matter, where the difference failed to reach statistical significance.
Similarly, microglial pathology detected by Iba1 IHC was
significantly more extensive in all areas analyzed here (p,0.05
each), with the exception of the LSC. TDP-43 pathology was
significantly more extensive in the motor cortex of patients who
showed a rapid progression of disease (p=0.04), although no
difference between patients with a fast and slow progression of
disease was observed in any other region of the neuraxis analyzed
here.
As we observed microglial pathology to correlate with disease
progression, we next asked if it would also be associated with
motor deficits as measured by clinical rating scales including a
novel score of UMN deficits. The median UMN score for this
cohort was 10 points (Table 1), with 25 patients scoring above
the median, and 26 patients scoring below/equal to the median
(for 9 patients, data on the UMN score was missing or
incomplete). Patients with an UMN score above the median
showed significantly more extensive microglial pathology in the
cervical anterior horns and CST as detected by both CD68 and
Iba1 when compared to patients who showed an UMN score
below/equal to the median (p=0.03 for each comparison).
Furthermore, we observed higher scores on the UMN scale to
correlate with more extensive microglial pathology in the cervical
CST as detected by staining for both CD68 (rho=0.54, p,0.01)
Figure 2. Microglial pathology, TDP-43, and neuro-axonal loss in the neuraxis of ALS. Bar plots show extent of microglial pathology as
detected by staining for CD68 (a) and Iba1 (b) as well as TDP-43 pathology (c) and myelin loss as an indirect measure of axonal loss (d) in different
regions of the neuraxis of ALS. For the spinal cord sections, the grey matter examined was the anterior horn and the white matter examined was the
anterior and lateral portion of the CST. Whiskers in bar plot indicate 95% confidence interval of mean. CSC = cervical spinal cord, grey = grey matter,
LSC = lumbar spinal cord, Med = medulla oblongata, motor = motor cortex (gyrus praecentralis), white = white matter.
doi:10.1371/journal.pone.0039216.g002
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with axonal loss as seen in KB staining in the cervical CST (rho
=0.471, p=0.007).
No significant differences regarding TDP-43 pathology were
observed between patients with an UMN score above or below
the median. No correlation of TDP-43 with microglial pathology
was observed in any of the areas analyzed here. No correlation of
the microglial markers (CD68, Iba1) or TDP-43 with the
ALSFRS-R or the MRCS was observed. No correlation of
postmortem interval to any of the markers analyzed here was
observed.
Microglial Pathology in ALS with/without C9ORF72
Repeat Expansion
To identify ALS cases with a C9ORF72 hexanucleotide repeat
expansion in our cohort, we analyzed all sporadic and familial
autopsy cases with ALS (n=57) for which a DNA sample was
available (DNA was not available for 2 cases). AC9ORF72
hexanucleotide repeat expansion was identified in 15.8% (9/57)
of ALS cases. For the subset of autopsy cases in which information
about family history was known a C9ORF72 expansion was
identified in 27.2% (3/11) of ALS cases with a family history of
ALS. The C9ORF72 expansion rate was 25% (3/12) in ALS cases
with a family history of neurodegenerative diseases other than
Figure 3. Microglial pathology and progression of disease. Bar plot shows microglial pathology as detected by staining for CD68 (a) and Iba1
(b) in ALS patients with a fast and a slow progression of disease. For the spinal cord sections, the grey matter examined was the anterior horn and the
white matter examined was the anterior and lateral portion of the CST. Whiskers in bar plot indicate 95% confidence interval of mean. CSC = cervical
spinal cord, grey = grey matter, LSC = lumbar spinal cord, Mot = motor cortex (gyrus praecentralis), Med = medulla oblongata, wh = white matter.
doi:10.1371/journal.pone.0039216.g003
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apparent sporadic ALS cases. The cohort included two with SOD1
mutations, none of which were found to have a C9ORF72
expansion.
Having identified nine ALS autopsy cases with a C9ORF72
repeat expansion, we asked if the presence of this repeat expansion
was linked to the clinical phenotype (Table 1). A bulbar onset of
disease was significantly more frequent in the C9ORF72 expansion
ALS cases as compared to non-expansion cases (p=0.04). Of 9
ALS cases with C9ORF72 expansion, 5 (55.6%) showed a bulbar
onset of disease, as compared to 26% in the subgroup of non-
expansion cases. There was a tendency towards a shorter disease
duration in the group with a C9ORF72 repeat expansion, though
this did not reach statistical significance (p=0.08). ALS cases with
C9ORF72 repeat expansion showed a significantly higher
ALSFRS-R as compared to non-expansion cases (p=0.03). There
was a tendency towards a higher MRCS in the expansion cases,
though this did not reach significance (p=0.09).
As the presence of C9ORF72 repeat expansions in ALS was
associated with alterations in clinical phenotype, we next asked if
this was associated with changes in microglial pathology. To
determine the extent and regional distribution of microglial
pathology in the neuraxis of ALS, the pathology labeled by
CD68 and Iba1 was rated on a semi-quantitative scale. ALS cases
with a C9ORF72 repeat expansion showed a tendency towards
more extensive microglial pathology in the grey and white matter
of the neuraxis that reached statistical significance in the white
matter of the medulla and the motor cortex (Figure 4). After
adjusting for disease duration using logistic ordinal regression, the
significance persisted for CD68 in the motor cortex (p=0.04) and
the medulla (p=0.01) white matter as well as for Iba1 in the
medulla white matter (p=0.02), while it was lost for Iba1 in the
motor cortex white matter (p=0.11). No significant difference
regarding the extent of TDP-43 pathology was observed between
cases with and without C9ORF72 repeat expansion in the regions
analyzed here.
Discussion
This study demonstrates that microglial pathology in the
neuraxis of ALS patients correlates with disease progression, and
shows it to be related to clinical UMN deficits, defining a novel
clinical score to assess UMN damage that reflects CST pathology.
It furthermore suggests that cases with a C9ORF72 repeat
expansion show more extensive microglial pathology in the motor
cortex and the medulla as compared to non-expansion cases.
Iba1 and CD68 as Markers of Microglial Activation in ALS
To analyze microglial pathology in the neuraxis of ALS, two
different IHC markers, CD68 and Iba1 were applied. CD68 is a
110 kDa glycoprotein that is part of lysosomal membranes and
shuttles in vesicles between lysosomes, endosomes, and the plasma
membrane [45,46]. CD68 is a pan-macrophage marker that is also
expressed in microglia [45,47]. The actin-binding protein IBA-1 is
an established IHC marker for microglia that has been shown to
be essential for membrane ruffling in response to macrophage
colony-stimulating factor and phagocytosis in cultured cells, and is
expressed on both resting as well as on activated microglia. [48–
53]. We observed Iba1 to delineate ramified microglia in the
neuraxis of ALS, whereas CD68 mainly stained intracellular
microglial cell compartments suggestive of endosomes/lysosomes
(Figure S1), indicating that Iba1 and CD68 could be of
complementary usefulness as markers of microglial pathology in
ALS.
Microglial Pathology is Related to CST Axonal Loss in ALS
To quantify microglial pathology in different regions of the
neuraxis of ALS, a semi-quantitative staging was applied. Our
observation of extensive microglial pathology immunoreactive for
CD68 and Iba1 confirms previous studies that demonstrated
widespread microglial pathology in the spinal cord of ALS [54–
56]. We observed the extent of microglial pathology to correlate
with axonal loss in the CST. This supports the notion that
proliferation and activation of microglia contributes to neurode-
generation in ALS, although it could merely be reactive to axonal
and myelin loss. Microglia activated through the so-called classical
pathway were shown to exert neurotoxic capacities through the
secretion of reactive oxygen species and pro-inflammatory
cytokines including TNF-a and IL-1b [57,58], and mutant
SOD1–expressing microglia were found to release higher levels
of pro-inflammatory and cytotoxic cytokines in comparison to the
wild-type microglia [59]. However, there is evidence that
microglial activation in ALS could be a ‘‘double edged sword’’,
with microglial cells also showing neuroprotective capacities by
releasing trophic and anti-inflammatory factors like IGF-1[60–62].
Therefore, microglia most likely have different phenotypic states
and can exert both toxic and protective effects on motoneurons
depending on the specific pathological conditions they encounter
[17,63].
Microglial Pathology is Related to Progression of Disease
and Clinical Signs of UMN Damage
Having observed microglial pathology to correlate with axonal
loss in the CST, we next asked if it was also related to the clinical
phenotype. While previous studies in rodents suggest an influence
of microglia on progression of disease [64,65], this has not been
conclusively demonstrated in humans so far. Our data suggests
that further understanding of the molecular pathology contributed
to by microglial cells could help to develop disease-modifying
therapies that reduce progression of disease benefiting patients
with sporadic and familial ALS. In line with previous studies
suggesting a deleterious loss of TDP-43 nuclear function could
contribute to neuronal damage in ALS [2,66], TDP-43 pathology
was more extensive in the motor cortex of cases that showed a
rapid progression of disease. However, no direct correlation of
TDP-43 pathology with neuronal or axonal loss was shown here,
which may be due to a clearance of TDP-43 from the extracellular
space following its release from degenerating neurons harboring
TDP-43 inclusions in the most severely affected regions of the end
stage ALS nervous system.
Our observation that microglial pathology in ALS correlates
with clinical signs of UMN damage is in line with observations of a
PET study using a ligand binding to a mitochondrial benzodiaz-
epine receptor that is activated in microglia showing microglial
activation to be associated with the clinical UMN ‘‘burden’’ [28].
So far, there is no widely accepted clinical scoring system to assess
UMN involvement in ALS [1], but we observed scores on the
novel UMN rating scale used in this study to correlate with both
axonal loss and microglial pathology in the CST. This study
thereby provides basic observations on this scoring system to assess
clinical UMN involvement that may validly reflect disease
pathology in the CST of ALS. The lack of correlation between
axonal loss and microglial pathology and the ALSFRS-R and the
MRCS probably reflects the fact that these scales are more
sensitive to lower motor neuron involvement and the resultant
muscle wasting than UMN damage [1,28].
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We next asked if the presence of C9ORF72 repeat expansions in
ALS would influence microglial pathology and clinical phenotype.
Interestingly, and in line with a previous study [12], our subgroup
of ALS with C9ORF72 expansion showed a bulbar onset in over
50% of cases, as compared to a significantly lower frequency in the
subgroup of non-expansion cases (26%). Generally, a bulbar onset
of disease is clinically associated with speech and swallowing
difficulties early-on in the disease, and is usually observed in
approximately 25% of all ALS cases [1]. Our cases with C9ORF72
expansion showed more extensive microglial pathology in the
motor cortex and the medulla, while the difference as compared to
non-expansion cases was not significant for other regions (Figure 4).
It is so far unclear how C9ORF72 hexanucleotide repeat expansion
induces pathology and how this may in turn affect non-neuronal
cells. In normal individuals, at least three alternatively spliced
C9ORF72 transcripts (variants 1–3) are expressed in the brain.
Quantitative mRNA expression analysis indicated that the
Figure 4. Microglial pathology in ALS with/without C9ORF72 repeat expansion. Bar plot shows microglial pathology as detected by staining
for CD68 (above) and Iba1 (below) in ALS patients with and without presence of a C9ORF72 repeat expansion. For the spinal cord sections, the grey
matter examined was the anterior horn and the white matter examined was the anterior and lateral portion of the CST. Whiskers in bar plot indicate
95% confidence interval of mean. CSC = cervical spinal cord, gr = grey matter, LSC = lumbar spinal cord, Mot = motor cortex (gyrus praecentralis),
Med = medulla oblongata, wh = white.
doi:10.1371/journal.pone.0039216.g004
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variant 1 expression, leading to an overall reduction in
C9ORF72 transcripts [11]. On a speculative level, changes caused
by C9ORF72 transcription could (through a yet unknown
pathomechanism) be active further downstream in the patholog-
ical pathway of ALS, and influence inflammatory mechanisms
linked to microglial pathology. However, the differences between
C9ORF72 expansion cases and non-expansion cases could also be
partially due to the high proportion of bulbar-onset cases with a
shorter disease duration in the expansion group, and could
indicate reactive bulbar microglial activity in response to neuronal
loss.
This study is limited by the lack of normal controls included
here that do not allow to exclude that microglial alterations in ALS
as assessed by CD68 and Iba1 may be partially due to post-
mortem artifacts. However, given the statistical strength of the
alterations observed here for a large cohort of patients with ALS,
and previous studies by our group and others using the same
markers [20,67,68], we still feel confident that the alterations
observed here are valid and worthwhile relating.
Supporting Information
Figure S1 Microglial pathology as shown by CD68 and Iba1.
Double-labeling IF analyzed by confocal microscopy shows
immunoreactivity of microglia for Iba1 (green) and CD68 (red)
in the motocortex of an ALS autopsy case. While Iba1 depicts
microglial cell morphology, CD68 mainly stains dot-like intracel-
lular structures suggestive of endosomes/lysosomes; a) DAPI, b)
CD68, c) Iba1, d) Merge/DAPI.
(TIF)
Table S1 Detailed description of upper motor neuron clinical
score using a combined assessment of spasticity based on the
Ashworth Spasticity Scale [32] with reflex scoring, and rating of
pseudobulbar affect.
(DOC)
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